Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Iovance Biotherapeutics's Debt-to-EBITDA or its related term are showing as below:
IOVA'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.23 Med: -0.18 Max: -0.06
Current: -0.15
During the past 13 years, the highest Debt-to-EBITDA Ratio of Iovance Biotherapeutics was -0.06. The lowest was -0.23. And the median was -0.18.
IOVA's Debt-to-EBITDA is ranked worse than 100% of 291
companies
in the Biotechnology industry
Industry Median: 1.14
vs IOVA: -0.15
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Iovance Biotherapeutics Debt-to-EBITDA Related Terms
Iovance Biotherapeutics Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IOVA vs SNDX, GLUE, TYRA: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Iovance Biotherapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Iovance Biotherapeutics Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Iovance Biotherapeutics's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Iovance Biotherapeutics's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Iovance Biotherapeutics (IOVA) has a Debt-to-EBITDA of -0.17 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Iovance Biotherapeutics. According to the industry distribution chart, Iovance Biotherapeutics ranks #999999 out of 291 companies in the Biotechnology industry.
Is Iovance Biotherapeutics' Debt-to-EBITDA too high?
Iovance Biotherapeutics' current Debt-to-EBITDA is -0.17. Based on the distribution chart, Iovance Biotherapeutics ranks #999999 out of 291 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Iovance Biotherapeutics has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Iovance Biotherapeutics' Debt-to-EBITDA compare to SNDX and GLUE?
According to the Biotechnology industry distribution chart, Iovance Biotherapeutics ranks #999999 out of 291 companies for Debt-to-EBITDA. This places Iovance Biotherapeutics in the lower half of its industry. The industry median Debt-to-EBITDA is 1.14. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.14, based on 291 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Iovance Biotherapeutics. For the Biotechnology industry, the median Debt-to-EBITDA is 1.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Iovance Biotherapeutics's current Debt-to-EBITDA is -0.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Iovance Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Iovance Biotherapeutics (IOVA) is currently considered Possible Value Trap. The stock's GF Value™ is $19.06, compared to a current price of $4.66 — trading 75.6% below its estimated fair value. The current Debt-to-EBITDA is -0.17. Iovance Biotherapeutics' overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Iovance Biotherapeutics (IOVA), the current Debt-to-EBITDA is -0.17 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Iovance Biotherapeutics (IOVA) Overvalued in 2026?
Based on GuruFocus' analysis, Iovance Biotherapeutics stock appears to be undervalued.
The current stock price of $4.66 is trading 75.6% below its estimated GF Value™ of $19.06.
GuruFocus considers Iovance Biotherapeutics to be Possible Value Trap.
Key valuation signals for IOVA:
Debt-to-EBITDA: -0.17
GF Value™: $19.06 vs. price of $4.66 (75.6% below fair value)
No single metric tells the full story. See the IOVA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
44GF Score
Get the complete analysis for IOVA
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IOVA has been successfully added to your 
